<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795690</url>
  </required_header>
  <id_info>
    <org_study_id>iOM TAR</org_study_id>
    <nct_id>NCT01795690</nct_id>
  </id_info>
  <brief_title>Clinical Tumor Anemia Registry (TAR)</brief_title>
  <acronym>TAR</acronym>
  <official_title>Clinical Registry Describing Treatment Reality of Patients With Cancer-(Therapy)-Induced Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ASORS (Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin der Deutschen Krebsgesellschaft)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to record information of routine treatment of anemia in
      cancer patients in Germany. An overview of the current treatment of anemia in German
      outpatient centers and hospitals will be provided. Primary outcome parameters, e.g.
      improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of
      different treatments will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Documentation of therapies</measure>
    <time_frame>12 weeks per patient</time_frame>
    <description>Overview on the current routine treatment of anemia in cancer patients in Germany</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin levels and QoL</measure>
    <time_frame>12 weeks per patient</time_frame>
    <description>Effectiveness of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP).
Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.</description>
  </secondary_outcome>
  <enrollment type="Actual">1018</enrollment>
  <condition>Anemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with malignant diseases starting anti-anemic treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignant disease

          -  Hemoglobin level &lt; 11 g/dl (female) or &lt; 12 g/dl (male)

          -  Start of antianemic therapy no more than 7 days prior to informed consent

          -  Performance status 0 - 3 (Karnofsky-Index &gt;= 40%)

          -  Minimum age: 18 years

          -  Informed written consent

        Exclusion Criteria:

          -  Hypersensitivity against antianemic therapies

          -  Myelodysplastic Syndrome

          -  Experimental antianemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>iOMEDICO</name>
      <address>
        <city>Freiburg</city>
        <zip>79108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.hindawi.com/journals/anemia/2016/8057650/</url>
    <description>Study Results</description>
  </link>
  <results_reference>
    <citation>Steinmetz T, Schröder J, Plath M, Link H, Vogt M, Frank M, Marschner N. Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study-The Tumor Anemia Registry. Anemia. 2016;2016:8057650. doi: 10.1155/2016/8057650. Epub 2016 Feb 4.</citation>
    <PMID>26966573</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Cancer</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>FACT-An</keyword>
  <keyword>FACT-GP</keyword>
  <keyword>Erythropoiesis-Stimulating Agents (ESA)</keyword>
  <keyword>Epoetin</keyword>
  <keyword>Ferric Carboxymaltose</keyword>
  <keyword>Blood Transfusions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

